# Avaxia Biologics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/avaxia-biologics

- Industry: Biotechnology
- Headquarters: Lexington, US
- Website: www.avaxiabiologics.com
- Total disclosed funding: $13M
- Latest round: Series B (Jun 7, 2013)
- Investors on record: 14

## About

Avaxia Biologics is dedicated to developing innovative gut-targeted antibody therapeutics, focusing on treatments for inflammatory bowel diseases, including ulcerative colitis.Founded in 2005 and headquartered in Lexington, US, Avaxia Biologics specializes in antibody therapeutics for gastrointestinal conditions. The company has raised a total of USD 7.43 mn across several funding rounds, with the latest being a Venture Debt round of USD 3.1 mn in December 2014 from investors including Cherrystone Angel Group and Maine Angels. The firm has engaged in 8 deals to date.Avaxia Biologics specializes in the development of gut-targeted antibody therapeutics, with its primary product being AVX-470, a bovine polyclonal milk-derived anti-TNF antibody. This innovative therapy has demonstrated efficacy in treating ulcerative colitis (UC), as evidenced by successful results from Phase 1b clinical trials. The company’s technology allows for the creation of GI-stable recombinant monoclonal antibodies known as Avaximabs™, targeted for inflammatory bowel disease (IBD) in both pediatric and adult populations. This sector presents a market opportunity estimated at approximately USD 9 billion globally, particularly in regions with high prevalence rates of IBD, such as North America and Europe.Avaxia Biologics generates revenue through strategic partnerships and agreements focused on commercializing its proprietary gut-targeted therapeutics. The company aims to license its technology to other entities, facilitating the distribution of its flagship product, AVX-470, and other Avaximabs™. These collaborations often involve revenue-sharing models or direct sales to healthcare providers specializing in IBD treatment. The company's strong intellectual property portfolio, along with the recent orphan drug status granted by the FDA for pediatric IBD, enhances its revenue potential and market positioning.Avaxia Biologics plans to leverage its recent funding to advance the development of its gut-targeted therapeutics and explore new product launches. The company is focused on expanding into North America and Europe, where the demand for its therapies is substantial. Following the Venture Debt funding in December 2014, Avaxia is poised to enhance its research efforts and pursue collaboration opportunities that align with its growth strategy.

## Funding rounds

- Series B, Jun 7, 2013, $7.4M — Keiretsu Forum, Tech Coast Angels, Golden Seeds, Launchpad Venture Group, Ariel Savannah Angels, AbbVie Ventures, Cherrystone Angel Group, Maine Angels
- Series B, Dec 18, 2012, $4M — Keiretsu Forum, Golden Seeds, Boston Harbor Angels, Launchpad Venture Group, Mass Medical Angels, North Country Angels, Cherrystone Angel Group, Beacon Angels, Maine Angels, Granite State Angels, Beta Fund
- Series A, Feb 14, 2012, $1.9M — Boston Harbor Angels, Launchpad Venture Group, Mass Medical Angels, North Country Angels, Cherrystone Angel Group, Beacon Angels

## Investors

- Boston Harbor Angels — Series A, Series B
- Launchpad Venture Group (https://capitalatlas.ai/funds/launchpad-venture-group) — Series A, Series B
- Mass Medical Angels — Series A, Series B
- North Country Angels — Series A, Series B
- Cherrystone Angel Group (https://capitalatlas.ai/funds/cherrystone-angel-group) — Series A, Series B
- Beacon Angels (https://capitalatlas.ai/funds/beacon-angels) — Series A, Series B
- Keiretsu Forum — Series B
- Golden Seeds (https://capitalatlas.ai/funds/golden-seeds) — Series B
- Maine Angels — Series B
- Granite State Angels — Series B
- Beta Fund (https://capitalatlas.ai/funds/beta-fund) — Series B
- Tech Coast Angels — Series B
- Ariel Savannah Angels — Series B
- AbbVie Ventures (https://capitalatlas.ai/funds/abbvie-ventures) — Series B